Fulcrum Capital’s AbbVie ABBV Stock Holding History

Fulcrum Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$459K	Sell	1,824 -510	-22%	-$110K	0.09%	69
2026 Q1	$508K	Sell	2,334 -232	-9%	-$51.5K	0.11%	62
2025 Q4	$586K	Hold	2,566	–	–	0.12%	58
2025 Q3	$594K	Hold	2,566	–	–	0.12%	56
2025 Q2	$476K	Hold	2,566	–	–	0.1%	66
2025 Q1	$538K	Buy	2,566 +587	+30%	+$114K	0.12%	58
2024 Q4	$352K	Hold	1,979	–	–	0.07%	87
2024 Q3	$391K	Hold	1,979	–	–	0.09%	79
2024 Q2	$339K	Hold	1,979	–	–	0.08%	81
2024 Q1	$360K	Hold	1,979	–	–	0.09%	79
2023 Q4	$307K	Hold	1,979	–	–	0.08%	90
2023 Q3	$295K	Hold	1,979	–	–	0.09%	82
2023 Q2	$267K	Sell	1,979 -525	-21%	-$77K	0.07%	97
2023 Q1	$399K	Buy	2,504 +987	+65%	+$151K	0.11%	75
2022 Q4	$245K	Hold	1,517	–	–	0.07%	93
2022 Q3	$204K	Buy	1,517 +100	+7%	+$14.3K	0.06%	78
2022 Q2	$217K	Buy	+1,417	New	+$217K	0.07%	70
2021 Q3	–	Sell	-3,555	Closed	-$400K	–	89
2021 Q2	$400K	Sell	3,555 -799	-18%	-$90K	0.1%	59
2021 Q1	$471K	Sell	4,354 -254	-6%	-$27.2K	0.14%	56
2020 Q4	$494K	Buy	+4,608	New	+$443K	0.15%	52
2020 Q3	–	Sell	-2,282	Closed	-$224K	–	62
2020 Q2	$224K	Buy	+2,282	New	+$201K	0.08%	64
2020 Q1	–	Sell	-2,282	Closed	-$202K	–	63
2019 Q4	$202K	Buy	+2,282	New	+$189K	0.06%	73
2019 Q2	–	Sell	-2,896	Closed	-$233K	–	61
2019 Q1	$233K	Buy	+2,896	New	+$237K	0.09%	58

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fulcrum Capital's ABBV Position: Q2 2026 in Review

Fulcrum Capital reduced its AbbVie (ABBV) stake by 22% in Q2 2026, selling an estimated $110K and leaving 1,824 shares worth $459K. The position accounts for 0.09% of the portfolio, ranked #69.

Fulcrum Capital first reported a position in ABBV in Q1 2019 and has held it in 23 quarters since. The position peaked at $594K in Q3 2025. 4,216 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Fulcrum Capital held 1,824 shares of AbbVie worth $459K as of Q2 2026.
Fulcrum Capital sold 510 AbbVie shares in Q2 2026, an estimated $110K.
AbbVie made up 0.09% of Fulcrum Capital's portfolio in Q2 2026, its #69 holding.
Fulcrum Capital first reported a position in AbbVie in Q1 2019 and has held it in 23 quarters since.
Fulcrum Capital's AbbVie position peaked at $594K in Q3 2025.
4,216 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Fulcrum Capital's 13F filing for Q2 2026, filed 21 Jul 2026.